Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?

MLA

Watson, Geoffrey Alan, et al. “Novel Strategies in Immune Checkpoint Inhibitor Drug Development: How Far Are We from the Paradigm Shift?” British Journal of Clinical Pharmacology, vol. 86, no. 9, Sept. 2020, pp. 1753–68. EBSCOhost, https://doi.org/10.1111/bcp.14355.

APA

Watson, G. A., Doi, J., Hansen, A. R., & Spreafico, A. (2020). Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift? British Journal of Clinical Pharmacology, 86(9), 1753–1768. https://doi.org/10.1111/bcp.14355

Chicago

Watson, Geoffrey Alan, Jeffrey Doi, Aaron Richard Hansen, and Anna Spreafico. 2020. “Novel Strategies in Immune Checkpoint Inhibitor Drug Development: How Far Are We from the Paradigm Shift?” British Journal of Clinical Pharmacology 86 (9): 1753–68. doi:10.1111/bcp.14355.